A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.

被引：0
|
作者：
Yang, Bo
Xiong, Qi
Song, Qi
Long, Yaping
Guo, Gang
Li, Hongzhao
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Oncol, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China
[4] Med Ethics Comm Chinese PLA Gen Hosp, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Urol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma of the urothelium
    von der Maase, H
    Lehmann, J
    Gravis, G
    Joensuu, H
    Bihn, B
    Geertsen, P
    Gough, J
    Chen, ZJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 400S - 400S
  • [42] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast carcinoma.
    Baltali, E
    Güler, N
    Özisik, Y
    Altundag, K
    Tekuzman, G
    ANNALS OF ONCOLOGY, 2000, 11 : 35 - 35
  • [43] Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.
    Han, Baohui
    Chen, Jianhua
    Wang, Ziping
    Li, Xingya
    Wang, Lin
    Wu, Lin
    Xie, Qiang
    Zhao, Yanqiu
    Wang, Mengzhao
    Lu, Junguo
    Shi, Huaqiu
    Ye, Feng
    Mei, Xiaodong
    Yao, Weirong
    Yue, Lu
    Jiang, Da
    Zhao, Jian
    Zhang, Shucai
    Chen, Gongyan
    Jiao, Shunchang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
    Ardavanis, A
    Tryfonopoulos, D
    Alexopoulos, A
    Kandylis, C
    Lainakis, G
    Rigatos, G
    BRITISH JOURNAL OF CANCER, 2005, 92 (04) : 645 - 650
  • [45] Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
    A Ardavanis
    D Tryfonopoulos
    A Alexopoulos
    C Kandylis
    G Lainakis
    G Rigatos
    British Journal of Cancer, 2005, 92 : 645 - 650
  • [46] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Chen, X.
    Li, W.
    Wu, X.
    Zhao, F.
    Wu, H.
    Gu, Y.
    Li, X.
    Qian, X.
    Hu, J.
    Li, C.
    Xia, Y.
    Yao, A.
    Seesaha, P. K.
    Shao, Q.
    Dong, X.
    Li, X.
    Shu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1305 - S1305
  • [47] Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
    Powles, Thomas
    O'Donnell, Peter H.
    Massard, Christophe
    Arkenau, Hendrik-Tobias
    Friedlander, Terence W.
    Hoimes, Chris
    Lee, Jae-Lyun
    Ong, Michael
    Sridhar, Srikala S.
    Vogelzang, Nicholas J.
    Fishman, Mayer N.
    Zhang, Jingsong
    Srinivas, Sandy
    Parikh, Jigar
    Antal, Joyce
    Jin, Xiaoping
    Gupta, Ashok Kumar
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [48] First-line of penpulimab and chemotherapy for advanced non-melanoma cutaneous carcinoma: A single center, single arm, exploratory study
    Xu, Jing
    Zhu, Dongyuan
    Liu, Zengjun
    Cui, Jinfang
    Liu, Mengyao
    Hu, Wenyu
    Xu, Ni
    Li, Minghuan
    Fu, Heng
    Zhao, Junkai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
    Rosenberg, Jonathan E.
    Flaig, Thomas W.
    Friedlander, Terence W.
    Milowsky, Matthew, I
    Srinivas, Sandy
    Petrylak, Daniel Peter
    Merchan, Jaime R.
    Bilen, Mehmet Asim
    Carret, Anne-Sophie
    Yuan, Nancy
    Sasse, Carolyn
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC).
    Chen, Xiaofeng
    Li, Wei
    Wu, Xiaofeng
    Zhao, Fengjiao
    Wang, Deqiang
    Wu, Hao
    Gu, Yanhong
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Li, Changxian
    Xia, Yongxiang
    Rao, Jianhua
    Yao, Aihua
    Seesaha, Poshita Kumari
    Shao, Qianwen
    Dong, XiaoWei
    Li, Xiangcheng
    Shu, Yongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345